• One-year, $12 million supply agreement signed with Tilray Inc. to support medical cannabis patients
• State-of-the-art hybrid greenhouse technology and cultivation operations enable 7ACRES to grow premier cannabis sustainably and at scale
• Ramping up to produce an estimated 50,000 kg at full capacity in 2019
• 7ACRES named ‘Brand of the Year’ at the 2018 Canadian Cannabis Awards

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) continues to build on its reputation as a global organization that produces and distributes consumer-centric, proprietary cannabis plant products. The company’s mission, aptly stated in an investor presentation (http://ibn.fm/gjNk3), is to “make a positive impact on people and the planet by continuing to grow better cannabis businesses globally.”

The Supreme Cannabis Company, through 7ACRES, its wholly owned subsidiary and award-winning Canadian Licensed Producer, provides a high-quality, premier product and brand that reflect the desires of a discriminating cannabis consumer. Company financials show that the 440,000-square-foot facility operated by 7ACRES in Ontario is on track to reach full production capacity in 2019.

7ACRES has received Health Canada approval to begin cultivating approximately 30,000 square feet of additional flowering rooms at its Kincardine, Ontario, facility, which raises the total flowering room space to 120,000 square feet (from 90,000 square feet) and increases the annual production capacity estimate to 17,500 kg (from approximately 13,300 kg), as detailed in a news release (http://ibn.fm/LmlII).

The facility’s potential capacity is expected to reach approximately 50,000 kg per year in 2019 due to increased production efficiencies and the completion and licensing of all 25 flowering rooms. 7ACRES also received licensing approval for production space designated for plant micropropagation, which Supreme Cannabis will begin at the facility to bring additional agricultural sciences to its high-quality cannabis production.

“Scaling our 7ACRES facility is a top priority and today’s announcement is another significant step forward towards completing that goal,” Supreme Cannabis president and founder John Fowler said in the January 28 news release. “7ACRES-branded dried flower has received enthusiastic reviews from consumers across Canada. With this additional production capacity, we’ll be able to better satisfy the demand from cannabis enthusiasts coast-to-coast.”

Shipments of the 7ACRES-branded high-end cannabis products have already been made to six of Canada’s provinces through distribution agreements made with provincial government channels. The company announced in early February that it has entered into supply agreements with two additional provinces (http://ibn.fm/jY1QC).

In December, 7ACRES was recognized as ‘Brand of the Year’ at the 2018 Canadian Cannabis Awards presented by Lift & Co. (TSX.V: LIFT). The Canadian Cannabis Awards celebrate Canadian cannabis, distinguishing the people, companies and products that make it great. The award recognizes the enormous effort behind creating a brand, strategy, culture, image and impact that resonate in the public consciousness (http://ibn.fm/cThSQ).

A recent article in MarketRealist.com reviewed several analysts’ recommendations for the company’s stock, noting that Supreme Cannabis has provided an impressive return of 47 percent year-to-date. Among the summarized comments, the article points out that Cormark Securities raised Supreme Cannabis’ target rating to a ‘Buy’, bringing it in line with several other analysts’ recommendations (http://ibn.fm/aNQRz).

The company’s growth strategy includes a C$12 million supply agreement with Tilray Inc. (NASDAQ: TLRY), a global leader in cannabis research, cultivation, processing and distribution, to supply dried cannabis for one year in support of medical cannabis patients in Canada. Supreme Cannabis has also partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste and Zenabis, among others. In addition, through a distribution partnership with Medigrow Lesotho (PTY) Limited, the company intends to export CBD and cannabis oil to international markets in the European Union and South America.

For more information, visit the company’s website at www.Supreme.ca

• Growcentia manufactures organically-derived plant biostimulants
• The company is developing premier probiotic products for agriculture
• Growcentia’s market-leading organic brand is Mammoth Microbes

Headquartered in Fort Collins, Colorado, Growcentia focuses on enhancing plant growth and minimizing the environmental impacts of agriculture. The company increases crop yields by enhancing nutrient use efficiency with advanced microbial probiotics (live microbes). Growcentia employs a proprietary method developed by a team of PhD soil microbiologists. This innovative method creates a consortia of bacteria that have synergistic qualities for vital nutrient cycling functions in the growing cycle and are highly effective. Therefore, Growcentia is able to combine the most functionally effective species to deliver innovative solutions to growers.

Fundamentally, Growcentia targets naturally occurring soil microbes that perform a specific nutrient cycling function; it then creates and manufactures organically-derived plant biostimulants, providing a solution for that function. Its products work to help growers and farmers maximize the health of their soils or growth media and increases nutrient uptake. The company’s emphasis is on boosting plant health, quality and yields, while at the same time decreasing fertilizer runoff.

Microbes colonize the soil and release enzymes. They are used by plants to increase nutrient uptake and promote strong growth. Growcentia notes that “functionally targeted microbials can greatly enhance the bio-availability of nutrients, boost disease resistance, inhibit the growth of parasites, and enhance drought tolerance”. The company’s manufacturing process utilizes plant extracts as a foundation for microbial growth in commercial-sized bio-reactors.

Danfeng Song, Salam Ibrahim and Saeed Hayek, in the book Recent Application of Probiotics in Food and Agricultural Science (http://ibn.fm/gXVGM), stated, “The plant probiotic bacteria have been isolated and commercially developed for use in the biological control of plant diseases or biofertilization. These microorganisms have fulfilled important functions for plant[s] as they antagonize various plant pathogens, induce immunity, or promote growth.”

Growcentia is concentrating on further developing first-rate biostimulant products for the high value specialty crop agricultural industry. Its main microbial brand is Mammoth, and its market-leading phosphorous solubilizing technology product is Mammoth P. The Mammoth brand is focused on delivering innovative solutions to the cannabis and hemp industry, and it is seeing great adoption with both indoor and in-field cultivators. The company’s P technology is university-tested by scientists at Colorado State University and is a patented, OMRI-certified natural product.

The company’s Mammoth P (phosphorous) for maximizing yield and quality was the first functionally-targeted, organically-derived microbial inoculant for the cannabis and hemp industry. It is a liquid formula of beneficial bacteria. Mammoth P can be applied directly to soil, coco or other growth media, as well as recirculating hydroponic systems. It is scientifically proven to grow bigger buds (http://ibn.fm/x7Zmc). Mammoth P is proven to increase dry weight yields by, on average, 16 percent across all management practices and nutrient lines. The beneficial bacteria in Mammoth P are akin to enzyme factories. They continually make enzymes in the growth media and root zone to assist in delivering nutrients to plants.

Growcentia, with its unique products and dedication to better and sustainable agriculture, is moving forward with advanced microbial additives. With its commitment to quality, the company extensively tests all of its products in the laboratory, greenhouse and field to guarantee effectiveness. Growcentia’s goal is to develop and market premier agricultural products and practices that benefit farmers and consumers alike.

For more information please visit www.Growcentia.com and www.MammothMicrobes.com

• QMC Quantum Minerals has focused its pursuit of lithium on an historically developed, spodumene-bearing mine site in southeastern Manitoba
• QMC is building on pegmatite channel sample assay analyses, with plans toward identifying an NI 43-101-compliant resource that’s greater than those historically reported
• The company is working with SGS Canada to expand the historical resource estimate for the property and expects to double its current resource

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ) has entered its first phase of diamond drill exploration on the spodumene-bearing Irgon pegmatite dike, which hosts a historical resource of 1.2 million tons grading 1.51 percent Li2O. The Irgon Dike is located in southeastern Manitoba within the Cat Lake-Winnipeg River pegmatite field, which hosts not only the adjacent, world class TANCO pegmatite but also numerous other spodumene and rare-element-bearing pegmatites. With the published historic resource to build on, the Irgon Dike is expected to yield significant quantities of saleable lithium.

Lithium remains an important lightweight metal that plays a key role in lithium-ion batteries that power the modern generation of computerized electronics — from small, wearable devices through larger electric vehicle batteries to the large electrical grid temporary energy storage units.

The company’s flagship project, the Irgon Lithium Mine Property, is located in a historically productive region, immediately north of the past-producing TANCO Mine. QMC aims to deliver a NI 43-101-compliant resource estimate on the site’s mineral potential this year that will supersede the historical resource estimate published for the Lithium Corporation of Canada (“LCOC”). LCOC undertook a 25-hole diamond drill program and underground development on the dike during the mid-1950s, the results of which were utilized to calculate that the Irgon Dike contained more than 1.2 million tons of lithium ore, grading 1.51 percent Li2O over a strike length of 365 meters (1,197.5 feet) and to a depth of 213 meters (698.8 feet). The dike remains open to depth and along strike.

QMC is in the initial stages of planning a phase two drill program, which will be designed to test the Irgon Dike to depth, below the current 231-meter level to which mineralization has been defined. By testing the Irgon mineralization below this level along the entire strike length of the dike, QMC expects to add additional tons to the resource estimate for the property.

In January, the company announced that an industry standard mobile metal ion (“MMI”) soil geochemical orientation survey would be undertaken, overseen by its consultants, SGS Canada. The results of this survey suggested the presence of two lithium soil geochemistry anomalies which potentially overlie mineralized locations at the Irgon Property. The MMI process allows companies to detect the presence of mobile elements (in this case, lithium) which occurs in the overlying soil. The source of these mobile ions is buried spodumene mineralization in bedrock-hosted, lithium-bearing pegmatites. On receiving successful results from the initial orientation survey, QMC cemented its confidence in the MMI technique, and the company plans to use the process at other prospective resource areas within the Irgon Lithium Mine project area.

QMC believes that these two geochemical anomalies that were identified by the MMI orientation survey, located immediately north and south of the Irgon Dike, are related to buried, parallel, lithium-bearing pegmatite occurrences that have neither surface rock outcroppings nor visible ground level spodumene mineralization (http://ibn.fm/wzKhN). Additional MMI sampling is expected to be undertaken to further define these targets, which will subsequently be drill tested during the phase two program.

QMC is also negotiating with SGS to process a large pegmatite sample obtained from the Irgon Dike to determine its lithium content. The study would have SGS prepare the pegmatite sample for a dense media separation (“DMS”) process. Magnetic minerals will then be removed, and a lithium concentrate will be made using DMS, after which the lithium concentrate will be converted to a potentially saleable product through flotation technology.

According to a new analysis by ResearchAndMarkets.com (“RAM”), the lithium-ion battery market is expected to grow at a CAGR of 16.2 percent between 2018 and 2024, landing at $92.2 billion in revenue (http://ibn.fm/POvCc). RAM further reported that the sales volume of new energy vehicles rose by 53.3 percent year-over-year during 2017 in China, the world’s largest emerging market for such vehicles (http://ibn.fm/R0yd2). All of these items point toward the rising potential of an industry for North America-based lithium producers.

For more information, visit the company’s website at www.QMCMinerals.com

• Company recently signed letter of intent with the Société québécoise du cannabis
• Its production capacity is expected to increase by 170,000 lbs. through phase four
• Organigram’s growth plans expand beyond Canada and into the global cannabis market

Organigram Holdings Inc. (TSX.V: OGI) (OTCQX: OGRMF), a licensed producer of cannabis and cannabis-derived products in Canada, recently announced that it has signed a letter of intent with the Société québécoise du cannabis (“SQDC”) (http://ibn.fm/eboHc). OGRMF’s wholly owned subsidiary, Organigram Inc., is focused on producing the highest quality, indoor-grown cannabis for recreational and condition-specific medical use. The new agreement with SQDC makes the company one of only three licensed producers in Canada to have secured distribution agreements in all 10 Canadian provinces.

Organigram believes in investing in the continuous growth of clients, employees and the community. Based in the heart of Atlantic Canada, the company is strongly committed to improving the quality of life of Canadians by effectively providing quality products, creating jobs, being a good neighbor and contributing to the community.

Organigram began in 2013 as a medical cannabis company with 100 percent organic production in prefabricated grow pods. In September 2017, Organigram signed the first recreational cannabis supply agreement in Canada with the Province of New Brunswick. As of February 2019, the company has distribution agreements in all 10 Canadian provinces. When the Canadian adult recreational cannabis market legalized on October 17, 2018, Organigram was ready with a portfolio of recreational product lines.

Currently in the third phase, the production capacity of OGRMF’s state-of-the-art facility is at 36,000 kg (79,000 lbs.) per year. The fourth phase is already underway and will bring the facility’s production capacity to 113,000 kg (249,000 lbs.) by fall 2019. The company boasts the lowest cost of cultivation among Canadian licensed producers, driven by industry-leading yields.

Now that it has secured all 10 provinces, OGRMF’s eyes are no longer solely on Canada. The company is working on international business partnerships and has developed a portfolio of legal adult-use recreational cannabis brands that includes the Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram has already begun exporting products from Canada and is anticipating a promising future.

For more information, visit the company’s website at www.Organigram.ca

• Under new distribution agreements, ETST is targeting new markets for its hemp CBD products
• Sales of cannabis-based pharmaceuticals are projected to account for 10 percent of the $31.6 billion legal cannabis market by 2022
• ETST has expanded its sales team as it seeks product placement in health food stores and large chains
• Company-sponsored foundation recently achieved non-profit status to advance research on cannabinoids

Earth Science Tech Inc. (OTCQB: ETST), a biotech company focused on the nutraceutical and pharmaceutical fields, is looking to expand its cannabidiol (“CBD”) product distribution in wider markets in the United States. The company has reached agreements with CannaBiz and Desert Sun Distribution to sell its CBD product line to chiropractors, dispensaries, pharmacies, health care practitioners, athletic clubs and clinics throughout the country (http://ibn.fm/5CRl6).

A new report by Arcview Market Research in partnership with BDS Analytics focuses on medical cannabinoid pharmaceuticals. The research makes clear that consumer respondents are turning to marijuana for relaxation and pain relief. Cannabis-based pharmaceuticals are projected to reach 10 percent of an estimated $31.6 billion legalized cannabis market by 2022, the report finds (http://ibn.fm/GuGyU).

ETST’s full-spectrum cannabinoids may offer analgesic pain relief and anxiety reduction. ETST distributes cannabinoids in the form of soft gels, tablets, liquids and other forms classified as food-based and permissible in all 50 states and some 40 countries. Pharmacies represent a key new market for ETST.

David Burbash, chief sales officer of ETST, is increasing the size of the company’s sales team as the company expands its target markets to include health food stores and large chains. By reaching agreements with CannaBiz and Desert Sun Distribution, ETST is raising the profile of its CBD products.

ETST is also expanding its sales reach into Mexico and South America through its distribution agreement with partner Forzagen. In a news release (http://ibn.fm/gb0x2), ETST president and Chairman Nickolas S. Tabraue said, “We expect to gain great exposure and additional revenue through this strategic partnership.” He added (http://ibn.fm/RijeU), “We are positioned to catapult in 2019.”

In addition, ETST has announced that Earth Science Foundation, Inc., the creation of which it has supported, is now a 501(c)(3) organization. Obtaining non-profit status enables the foundation to accept tax-free contributions that will fund further studies of cannabidiol products with a primary objective of helping those who suffer from cancer, epilepsy, depression, autism, chronic pain, dementia, drug/alcohol addiction, and AIDS (http://ibn.fm/uH48K).

For more information, visit the company’s website at www.EarthScienceTech.com

• SinglePoint’s horizontally established portfolio is primed for exponential profit growth with the announcement of asset acquisition, capitalization plans
• The company’s plans to acquire solar energy business Direct Solar and solar marketer AI Live Transfers mark entry into industry eyeing $57.3 billion by 2022
• Letter of intent anticipates raising up to $12 million to fund hemp-derived CBD opportunities amid projections of $22 billion market by 2022
• SinglePoint is also investing in efforts to develop specific strains of CBD through the photobioreactor process

Continued interest in energy systems that are friendly to the planet’s environment is creating new opportunity for exponential growth at SinglePoint Inc. (OTCQB: SING), a diversified holding company specializing in M&A activity that promotes new technologies. On February 26, SinglePoint announced that it has signed an agreement to acquire Direct Solar and AI Live Transfers – two companies utilizing the Lending Tree Model to market products and services to solar power consumers (http://ibn.fm/6fZ3Z).

The Lending Tree Model involves the use of technology to connect people seeking loans with a variety of loan providers nationwide, so they can shop for a service that most closely suits their needs. SinglePoint’s asset purchase agreement with the two solar industry products, services and marketing enterprises follows its own model of establishing a horizontal industries portfolio comprising undervalued companies that will benefit from the injection of growth capital and technology integration.

The acquisition agreement granting Direct Solar and AI Live Transfers more than $2 million in SinglePoint common stock shares and a 49 percent ownership interest in a funded subsidiary gives SinglePoint a toehold in the solar energy industry at a time when multinational concerns over climate change are driving governmental, corporate and consumer interests toward renewable power sources such as solar (http://ibn.fm/WuxRl). Analysts at Zion Market Research forecast global solar panel industry growth, with a CAGR of 10.9 percent between 2017 and 2022, landing at $57.3 billion by 2022 (http://ibn.fm/4CYod).

Additionally, SinglePoint plans to use proprietary technology that Direct Solar has developed to educate sales representatives around the nation to quickly scale the business. This acquisition also enables SinglePoint to tap into cannabis businesses nationwide regarding opportunities to save money and increase their margins through the use of solar to lower utilities expenses. SinglePoint expects to begin realizing profits from the Direct Solar acquisition by April. AI Live Transfers is a company that uses artificial intelligence in the marketing arena to progressively seek out potential customers using a strategy that maximizes closing agents’ time (http://ibn.fm/Dz4aq).

“This is a phenomenal opportunity for SinglePoint. This changes the entire financial fundamentals for the company and enables us to continue to push forward with opportunities to continue increasing shareholder value and the overall value of SinglePoint,” SinglePoint President Wil Ralston stated in a news release.

The company has also announced a letter of intent to raise up to $12 million to capitalize on a wide variety of opportunities in the hemp-derived CBD space (http://ibn.fm/5k63J). SinglePoint has been highly focused on the hemp market through its SingleSeed.com subsidiary and is establishing a place in the CBD market supply chain.

“We are already filling multiple orders and will be able to expand our sales and marketing as well as receive the best pricing from our suppliers with larger purchase orders” once the funding proposal is completed, SinglePoint CEO Greg Lambrecht added.

The company has also invested in TorusMed – a business using commercial-size photobioreactors in its efforts to produce specific strains of CBD. Cannabis industry analysts at the Brightfield Group predict that the hemp-derived CBD market could reach $22 billion by 2022, demonstrating the potential of progressively investing in business growth in that space (http://ibn.fm/gOpUo).

For more information, visit the company’s website at www.SinglePoint.com

• Proprietary targeted immunotherapy technology personalized to match unmet needs of advanced breast cancer patients
• Ongoing clinical studies of lead candidate, Bria-IMT, continue to show robust biological activity, excellent safety profile
• Breast cancer is one of the most commonly diagnosed cancers, with 2.1 million new cases expected in 2018
• Global cancer immunotherapy market is projected to be valued at nearly $145 billion by 2022

An equity investment of C$500,000 into BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) by the company’s recently-appointed director, Jamieson Bondarenko (http://ibn.fm/okWzb), underscores the vital importance of BriaCell’s proprietary drug development efforts to millions of cancer patients. BriaCell is an immuno-oncology-focused biotechnology company dedicated to developing the first off-the-shelf, personalized immunotherapy that specifically targets the unmet medical needs of advanced breast cancer patients (http://ibn.fm/4OLjo).

In a news release outlining the non-brokered private placement financing, the company said that net proceeds from the offering would be primarily used to finance BriaCell’s IIa combination study of Bria-IMT with KEYTRUDA (by Merck & Co., Inc.) in advanced breast cancer patients, in the pursuit of other research opportunities, and for working capital and general corporate purposes (http://ibn.fm/yMQfi). The combination study is listed in ClinicalTrials.gov as NCT03328026.

“In my view, owning a meaningful percentage of BriaCell’s equity while funding clinical work will align the company’s capital markets strategy with its drug development objectives,” Bondarenko stated in the news release. “The importance of accelerating this work is evidenced in efficacy data of BriaCell’s Phase I/IIa study of Bria-IMT and safety data of the Bria-IMT KEYTRUDA combination study in advanced breast cancer. There exists a unique opportunity to advance BriaCell’s remarkable achievements on behalf of breast cancer patients, survivors and deceased, and their families.”

Bondarenko will purchase five million common shares of the company at a price of C$0.10 per common share for gross proceeds of C$500,000 (the “offering”). Upon closing of the offering, which is subject to final approval from the TSX Venture Exchange, Bondarenko will have beneficial ownership of an aggregate of 23,070,500 common shares, representing approximately 13.7 percent of BriaCell’s issued and outstanding common shares.

“I am delighted with the commitment Jamieson has shown to BriaCell,” Dr. William Williams, BriaCell’s president & CEO, stated in the release. “He is a core influential shareholder and now a Director who believes in our mission and is working to advance our science as we develop novel and effective ways to combat breast cancer.”

Bria-IMT activates the immune system to destroy cancer cells in a way that’s believed to be both unique and more effective than other, similar approaches. Bria-IMT has shown promise in FDA-approved clinical trials, suggesting excellent safety and efficacy in patients who matched the Bria-IMT HLA types. BriaCell provided initial safety data on the Bria-IMT/KEYTRUDA combination study and additional confirmatory phase I/IIa data from the Bria-IMT monotherapy study at the 2018 San Antonio Breast Cancer Symposium (http://ibn.fm/r67pW). BriaCell also recently announced the initiation of clinical use of a novel frozen formulation of Bria-IMT for on-demand shipment to clinical sites to accommodate higher patient volumes at reduced per-dose costs (http://ibn.fm/JeZzu).

ResearchAndMarkets reports that the global cancer immunotherapy market is projected to grow rapidly in the coming years, expanding at a CAGR of nearly 13 percent through 2023 (http://ibn.fm/6N4aC). By 2022, the market volume is expected to exceed $145 billion (http://ibn.fm/P908A).

For more information, visit the company’s website at www.BriaCell.com

• Sharing Services offers multiple services aimed at promoting the growth of subsidiary companies in the direct selling industry
• One such subsidiary, Elepreneurs, has grown since its initial launch in December 2017 to over 150,000 customers
• Elepreneurs maintains a loyal customer base through its unique products that deliver results

Sharing Services Inc. (OTCQB: SHRV), a diversified holdings company focused on reshaping the way modern entrepreneurs succeed, offers over 25 years of leadership in the direct selling industry. The company employs a dynamic business model which focuses on mentorship of subsidiary companies. Sharing Services specializes in offering management, buying power, merchant processing, manufacturing and administrative services, enabling mentee companies to develop and expand.

Sharing Services focuses on companies operating in the direct selling industry. These companies either sell products directly to consumers or offer services in various fields, including health and wellness, energy, technology, insurance services, training, media and travel benefits. By having a vested interest in the continued success of several direct selling companies, Sharing Services (http://ibn.fm/vyexH) aims to “revolutionize the model in the direct selling industry.”

One of Sharing Services’ popular brands is Elevacity Global (http://ibn.fm/wNH42), which is focused on elevating consumers’ “health, wealth, and happiness through patented and powerful nutritional consumer products.” Customers have grown to trust Elevacity for its unique products that deliver results. One such supplement is Xanthomax (http://ibn.fm/fLRaJ), a best-selling product and “powerful antioxidant that assists in elevating mood.” The brand also offers products to enhance sleep and energy for consumers.

Another branch of Sharing Services’ success is Elepreneurs LLC, a wholly owned subsidiary of the company. Elepreneurs has seen vigorous success since it was launched in December 2017 and currently services over 150,000 customers throughout the United States. Its Elepreneurs, also known as independent contractors, share the company’s line of Elevacity products with others, seeing part-time profits individually and enticing fans of the Elevacity product line to join the Elepreneurs team as well.

Sharing Services has structured Elepreneurs to contract with other companies, utilizing the direct selling model to promote and sell products. In a recent news release, Robert Oblon, founder and CEO of Elepreneurs, discussed how the Elevacity line has attracted a diverse group of individuals to the entrepreneurial business model (http://ibn.fm/YAT1c). “We saw that people were sharing their experiences with our Elevacity products, and many customers became interested in selling the products,” he stated. “As a result, we have attracted people from various backgrounds who are building their own home-based businesses.”

For more information, visit the company’s website at www.SHRVInc.com

• Clean, controlled cultivation eschews use of radiation to destroy pests and pathogens
• Analysts at Jefferies recently initiated coverage of FLWR
• Flowr has applied for Nasdaq Listing

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) is growing cannabis with TLC as well as THC. The Health Canada Licensed Producer (“LP”) of cannabis, founded by MedReleaf co-founder Tom Flow and a team of industry pioneers, is out to generate premium, non-irradiated product at high yields. The company expects its ability to produce clean cannabis at consistently high quality to be a crucial differentiating factor as the medical and recreational markets in Canada develop.

Its shares may soon be trading on the Nasdaq. The company recently submitted an application to list its common shares on the Nasdaq Capital Market and has filed a Form 40-F Registration Statement with the U.S. Securities and Exchange Commission (“SEC”) (http://ibn.fm/WHWYs). The listing of Flowr’s shares on the Nasdaq will be subject to a number of regulatory requirements, including registration of the common shares with the SEC and a determination by the Nasdaq that Flowr has satisfied all applicable listing requirements. Subject to approval for listing, the company’s common shares will continue to trade on the TSX Venture Exchange (“TSX.V”) under ‘FLWR’. A trading date will be made public once all regulatory formalities are satisfied.

To the Flowr Corporation, cannabis is not just a commodity called ‘weed’. The company expects that the cannabis market will bear similarities to the market for wines. Both champagne and altar wine are made from grapes, but their quality and prices vary considerably. Flowr wants to produce “champagne cannabis.” As a result, it has set out to cultivate its cannabis in a controlled environment. Its flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, has been engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. Flowr knows that the psychoactive and therapeutic experience delivered by its product depends a lot on how it is grown, including how much light and water it’s given, when it’s pruned and when it’s given nutrients. As noted by CEO Vinay Tolia (http://ibn.fm/wsehA), “The plant needs a lot of TLC.”

Besides, getting Health Canada to approve facilities and product can be challenging. The Health Canada testing regime is so strict that many growers are unable to pass the microbial and yeast level standards. Consequently, they resort to a process called irradiation. Their final product is bombarded with gamma rays, which kill the mold, yeast and bacteria, but, as Tolia points out, would be the equivalent of telling consumers that it’s okay to eat moldy bread because it’s been exposed to gamma rays, something which, perhaps, they’ve only come across in sci-fi movies. The gamma radiation is typically produced by radioactive isotopes of cobalt. Companies that cannot produce clean cannabis, the way Flowr does, are compelled to go down this road, and approximately 80 percent of them do, according to Cannabis Tech (http://ibn.fm/PbvK5).

Exposing cannabis to radioactivity also changes the terpene profile of the plant. A recent study, published in a leading pharmacological journal, concluded that “…irradiation had a measurable effect on the content of various cannabis terpenes, mainly on the more volatile monoterpenes. In general, reduction of affected terpenes was between 10 and 20%, but for some components, this may be as much as 38%.” Terpenes are substances that are believed to be essential to the effectiveness of cannabinoids, a recognized phenomenon that has been dubbed the “entourage effect.”

Flowr’s cultivation program is led by co-founder and President Tom Flow, an industry pioneer who’s widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up protocols for that company’s flagship Marcum cultivation facility. MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In addition, analysts at Jefferies have now initiated coverage of several cannabis stocks, including positive coverage of FLWR, suggesting that the global cannabis industry could reach $130 billion by 2029 (http://ibn.fm/pix0e).

For more information, visit the company’s website at www.Flowr.ca

• TGOD’s 49.18 percent interest in Jamaican cannabis company Epican includes cultivation, extraction, manufacturing facilities and retail distribution licenses
• Expansion of production capacity on the 100-acre site is timed to build inventory by up to 14,000 kg to meet forecast retail demand
• Flagship Kingston retail location continues to increase in month-over-month sales growth
• Company is testing the first high-tech medical cannabis vending machines using built-in biometric security features

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a cannabis-focused research and development company, and its Jamaican partner, Epican Medicinals Ltd. (“Epican”), are celebrating significant milestones toward establishing a leadership position in the island nation’s robust medical cannabis market. TGOD’s strategic partnership with Epican, first announced in June 2018 as an investment for a 49.18 percent interest in the company, serves the medical cannabis needs of Jamaica’s three million residents and nearly 4.3 million tourists (http://ibn.fm/KHVxG).

The relationship has been marked by nonstop highs for the partners, Brian Athaide, director and CEO of TGOD, stated in a news release (http://ibn.fm/PeHCP). Highlights of an eventful 2018 are reviewed in the release, which includes praise for the founders of Epican – brothers Dwayne and Karibe McKenzie – as the Jamaican cannabis company continues to break new ground in the Caribbean island nation. The McKenzie brothers have been at the forefront of Jamaica’s burgeoning medical cannabis industry for years, securing the island’s historic first license to cultivate cannabis, according to an article in The Gleaner (http://ibn.fm/DjKUw).

TGOD’s recent list of achievements with Epican includes leasing a 100-acre parcel of land in Trelawny Parish to increase cannabis production toward a 14,000 kg operation with the potential for further expansion. This accelerated production capacity growth is designed to build inventory in advance of expanding retail locations at several strategic sites throughout Jamaica. Epican’s flagship site in Kingston continues to see increased sales month-over-month, while its Montego Bay retail location is awaiting authorization from the Cannabis Licensing Authority to open its doors. TGOD is also pursuing GMP certification at its Kingston Lab to facilitate global export to select international jurisdictions, as regulations permit.

“We have made incredible progress in Jamaica over the past eight months,” Athaide stated in the release. “We plan to continue opening stores throughout the country, increasing productive capacity, and expanding our leadership in Jamaica. As Trelawny comes online in phases, we will accelerate production to meet growing demand within Jamaica and export product through TGOD’s distribution channels in Mexico and beyond.”

Other highlights of the partnership include increasing Epican’s employee base from 17 to 40; piloting an industry-first prescription delivery program for registered medical patients that is expected to dramatically reduce delivery times; and testing of the first high-technology cannabis vending machines that utilize thumbprint scanners, ensuring product access to authorized patients only. A prototype of the medical cannabis dispensing machine is on display at an Epican retail location, and plans are in place to add more machines once necessary approval is received from the Cannabis Licensing Authority (http://ibn.fm/Ci3gi).

TGOD’s 49.18 percent Jamaican investment is an integral component of the company’s international strategy, together with distribution and operations in Europe, Latin America and North America. TGOD was recently classified in an institutional equity research report by CIBC World Markets as one of the few small- and medium-sized businesses that have what it takes to lead the new global cannabis market (http://ibn.fm/iv9IE).

For more information, visit the company’s website at www.TGOD.ca